---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-011209"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2021-08-11T23:59:59+00:00"
generated_at: "2026-06-29T15:11:28.919264+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma Q2 net loss $9.2M vs $3.7M; cash $167.3M; STRIDE study first patient dosed

## Summary
- Net loss of $9.2M ($0.43/share) for Q2 2021, compared to net loss of $3.7M ($1.82/share) in Q2 2020.
- Cash, cash equivalents and short-term investments of $167.3M as of June 30, 2021.
- First patient dosed in Phase 2b STRIDE trial of REN001 in primary mitochondrial myopathies (PMM); McArdle disease study enrollment completed.
- R&D expenses increased to $6.3M from $2.8M; G&A expenses rose to $2.9M from $0.9M.
- Anticipated milestones: McArdle results Q1 2022, LC-FAOD results H1 2022, FORWARD study results H2 2022.

## SEC filing metadata
- accession: 0001558370-21-011209
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2021-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000155837021011209/0001558370-21-011209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000155837021011209/rphm-20210811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-011209
- JSON: https://secwatch.observer/filing/0001558370-21-011209.json
- Plain text: https://secwatch.observer/filing/0001558370-21-011209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.